AbbVie M&A Buzz Sends Revolution Medicines RVMD Above $100, ABBV Stock $230+

Shares of AbbVie and Revolution Medicines climbed after reports surfaced that the pharmaceutical giant is in advanced discussions to acquire

Quick overview

  • AbbVie and Revolution Medicines' shares rose sharply after reports of AbbVie being in advanced talks to acquire the biotech firm.
  • Revolution Medicines' stock surged approximately 28%, surpassing the $100 mark for the first time, while AbbVie gained about 3.5%.
  • Analysts suggest that a formal offer for Revolution could come at a significant premium, given its current market capitalization of around $20 billion.
  • A deal could be finalized soon, pending any unforeseen complications.

Shares of AbbVie and Revolution Medicines climbed after reports surfaced that the pharmaceutical giant is in advanced discussions to acquire the oncology-focused biotech firm.

Acquisition Talks Drive Market Reaction

AbbVie and Revolution Medicines both moved sharply higher on Wednesday following a Wall Street Journal report indicating that AbbVie is in advanced talks to purchase the cancer-drug developer. The report, citing people familiar with the matter, said negotiations are progressing, though the financial terms of a potential deal remain undisclosed.

Stocks React Strongly

Revolution Medicines shares surged roughly 28% during afternoon trading, breaking above the $100 level for the first time and extending a powerful multi-month rally. AbbVie stock also gained, rising about 3.5% to trade near $235 as investors reacted positively to the prospect of a strategic oncology acquisition.

RVMD Stock Chart Monthly – Rebounding Strongly Off the 50 SMA

Valuation in Focus

With Revolution’s market capitalization near $20 billion at current prices, analysts note that a formal offer could come at a meaningful premium, consistent with typical biotech acquisition structures. The stock has already gained more than 300% since September 2025, when shares were trading near $30, and the move above $100 has opened the door to further upside.

Deal Timing

According to the Journal, a transaction could be finalized in the near term, assuming no last-minute complications emerge.

ABOUT THE AUTHOR See More
Skerdian Meta
Lead Analyst
Skerdian Meta Lead Analyst. Skerdian is a professional Forex trader and a market analyst. He has been actively engaged in market analysis for the past 11 years. Before becoming our head analyst, Skerdian served as a trader and market analyst in Saxo Bank's local branch, Aksioner. Skerdian specialized in experimenting with developing models and hands-on trading. Skerdian has a masters degree in finance and investment.

Related Articles

HFM

Pu Prime

XM

Best Forex Brokers